|
1.
|
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 -  10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
|
2.
|
|
18 p, 862.2 KB |
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
/
Chari, Ajai (Mount Sinai School of Medicine, USA) ;
Askari, Elham (Hospital Universitario Fundación Jiménez Díaz) ;
Caers, Jo (Centre Hospitalier Universitaire de Liège, Belgium) ;
Costa, Luciano J. (University of Alabama at Birmingham, USA) ;
Hilder, Brandi W. (Janssen Research & Development, Spring House, USA) ;
Krishnan, Amrita (City of Hope Comprehensive Cancer Center, Duarte, USA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Minnema, Monique C. (University Utrecht, Netherlands) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pillarisetti, Kodandaram (Janssen Research & Development, Spring House, USA) ;
Van De Donk, Niels W.C.J. (Vrije Universiteit Amsterdam, Netherlands) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra)
What is this summary about? This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. [...]
2023 - 10.2217/fon-2023-0332
Future oncology (London, England), Vol. 19 Núm. 27 (september 2023) , p. 1823-1840
|
|
|
3.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
4.
|
|
12 p, 1.8 MB |
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
/
Leleu, Xavier (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Chou, T. (Niigata Cancer Center Hospital) ;
Dimopoulos, Meletios (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ;
Yoon, S. S. (Department of Internal Medicine. Seoul National University) ;
Prince, H. M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Pour, L. (University Hospital Brno (República Txeca)) ;
Shelekhova, T. (Clinic of Professional Pathology) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ;
Khurana, M. (Clinical Development. Oncology. Amgen Inc) ;
Zhang, J. (Global Biostatistical Science. Amgen Inc) ;
Obreja, M. (Global Biostatistical Science. Amgen Inc) ;
Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ;
Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020
|
|
|
5.
|
|
10 p, 667.7 KB |
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX
/
Kaufman, J. L. (Winship Cancer Institute. Emory University) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ;
Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ;
Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ;
Morton, J. (Icon Cancer Care) ;
Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ;
Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ;
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ;
Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ;
Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ;
Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ;
Kim, J. S. (Yonsei University College of Medicine. Severance Hospital) ;
Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Cochrane, T. (Gold Coast University Hospital and Griffiths University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
O'Rourke, L. (Janssen Research & Development) ;
Trivedi, S. (Janssen Research & Development) ;
Casneuf, T. (Janssen Research & Development) ;
Krevvata, M. (Janssen Research & Development) ;
Ukropec, J. (Janssen Global Medical Affairs) ;
Kobos, R. (Janssen Research & Development) ;
Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole) ;
Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ;
San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
